Daily Stock Analysis, CFRX, ContraFect Corp, priceseries

ContraFect Corp. Daily Stock Analysis
Stock Information
Open
1.57
Close
1.59
High
1.69
Low
1.57
Previous Close
1.58
Daily Price Gain
0.01
YTD High
2.31
YTD High Date
Mar 8, 2018
YTD Low
1.00
YTD Low Date
Jan 2, 2018
YTD Price Change
0.57
YTD Gain
55.88%
52 Week High
2.31
52 Week High Date
Mar 8, 2018
52 Week Low
0.80
52 Week Low Date
Sep 8, 2017
52 Week Price Change
-0.06
52 Week Gain
-3.64%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 15. 2017
1.75
Mar 1. 2017
2.10
9 Trading Days
19.74%
Link
LONG
Sep 27. 2017
1.02
Oct 11. 2017
1.19
10 Trading Days
16.77%
Link
LONG
Jan 3. 2018
1.03
Jan 17. 2018
1.14
9 Trading Days
10.49%
Link
LONG
Jan 26. 2018
1.25
Feb 9. 2018
1.48
10 Trading Days
18.20%
Link
Company Information
Stock Symbol
CFRX
Exchange
NasdaqCM
Company URL
http://www.contrafect.com
Company Phone
914-207-2300
CEO
Steven C. Gilman
Headquarters
New York
Business Address
28 WELLS AVENUE, 3RD FLOOR, YONKERS, NY 10701
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001478069
About

ContraFect Corp. is a clinical-stage biotechnology company. It focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. The company scientific and clinical strategy focuses on the use of combination therapies. ContraFect was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.

Description

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.